Document Type
Article
Publication Date
December 2023
Patent Number
11851707
CPC
C12Q 1/6883 , C12Q 2600/118 , C12Q 2600/158 , A61K 9/0043 , A61K 9/51
Abstract
A method of predicting the development of chronic lung allograft dysfunction (CLAD) in lung transplant patients using N-myc-interactor (NMI) as a biomarker and associated treatment thereof is presented. Also presented is a method of reducing the risk of CLAD by administering a therapeutic agent capable of increasing NMI in the patient. NMI is a critical regulator of epithelial-to-mesenchymal transition (EMT) and an important precursor to development of CLAD. NMI expression is reduced in CLAD patients and can be used as an early diagnostic biomarker to predict the development of CLAD. NMI can also be used as a drug target for a therapeutic to increase expression of NMI and treat chronic lung disease such as CLAD. Therapeutics comprising NMI protein or NMI gene can be used as potential treatments for chronic lung diseases such as CLAD.
Application Number
17/215249
Recommended Citation
Sharma, Nirmal S.; Banday, Mudassir; and Seyfang, Andreas, "N-Myc-Interactor protein as a marker for chronic lung disease and uses thereof" (2023). USF Patents. 1396.
https://digitalcommons.usf.edu/usf_patents/1396
Assignees
University of South Florida
Filing Date
03/29/2021
